Rockefeller and CNIC Advance Mass Spec Applications

A cluster of new mass spectrometry studies published in June 2026 highlights the growing sophistication of proteomics and metabolomics applications across drug discovery, disease biology and regenerative medicine. Reported by The Analytical Scientist on 30 June 2026, the research covers cell-type specific secretomes, cardiomyocyte metabolic reprogramming toward a regenerative state, and improved separation of host and microbial metabolite contributions to systemic biology, each drawing on advanced mass spec workflows.

Researchers at Rockefeller University have developed an in vivo proximity-labelling platform that traces secreted proteins back to specific cell types and follows how those signals change during fasting, inflammation and obesity. Published in Cell Reports, the workflow uses TurboID engineered into the endoplasmic reticulum of mice, biotinylating secreted and membrane proteins as they pass through the ER for enrichment and LC-MS/MS/MS analysis. Applied across metabolic states, the platform revealed distinct remodelling of adipocyte- and hepatocyte-derived proteomes and linked 65 stress-responsive proteins to type 2 diabetes, cardiovascular disease and sepsis via UK Biobank comparison.

A separate study from the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published in Genome Biology, used single-cell proteomics on adult mouse cardiomyocytes to link the Myc transcription factor to a pro-regenerative cellular state characterised by increased glycolysis and reduced fatty acid oxidation. The workflow analysed 647 cells and quantified 1,624 proteins, identifying a distinct regenerative subpopulation. Separately, isotope-tracing work in Nature Metabolism showed that many indole and phenol metabolites long attributed to the gut microbiome are also directly produced by mammalian cells, with implications for how microbiome studies interpret baseline metabolite levels.

Two commercial vectors stand out. The Rockefeller secretome platform maps directly onto pharma target discovery, particularly across metabolic and inflammatory disease. The CNIC cardiac regeneration data adds mechanistic weight to the ongoing interest in cardiomyocyte reprogramming, a space where multiple biotech developers are actively working. Expect increased pharma partnering conversations around mass spec-enabled target discovery through the rest of 2026.

For the latest updates and in-depth insights into the world of Analytical Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!